Skip to main content

Table 3 Changes in hemodynamic, blood gas parameters and organ function

From: IgM-enriched immunoglobulins (Pentaglobin) may improve the microcirculation in sepsis: a pilot randomized trial

 

Baseline

24 h

72 h

p (time)a

p (interaction)b

MAP (mmHg)

0.083

0.309

 Pentaglobin (n = 10)

80 ± 14

82 ± 9

86 ± 15

  

 Placebo (n = 9)

85 ± 15

75 ± 17

89 ± 13

  

HR (bpm)

0.662

0.169

 Pentaglobin (n = 10)

84 ± 23

85 ± 11

90 ± 21

  

 Placebo (n = 9)

95 ± 19

89 ± 30

80 ± 25

  

Norepinephrine tartrate (n, mcg/kg/min)

 Pentaglobin (n = 10)

8, 0.13 [0.03–0.39]

8, 0.12 [0.03–0.23]

7, 0.11 [0–0.38]

0.616

 

 Placebo (n = 9)

8, 0.38 [0.23–0.70]

8, 0.50 [0.14–0.70]

6, 0.10 [0–0.40]*

0.004

 

Arterial pH

0.110

0.377

 Pentaglobin (n = 10)

7.43 ± 0.07

7.42 ± 0.06

7.45 ± 0.07

  

 Placebo (n = 9)

7.45 ± 0.03

7.47 ± 0.05

7.49 ± 0.07

  

PaO2/FiO2 (mmHg)

0.875

0.474

 Pentaglobin (n = 10)

300 ± 89

311 ± 151

320 ± 89

  

 Placebo (n = 9)

311 ± 89

280 ± 74

262 ± 85

  

ScvO2 (%)

< 0.001

0.053

 Pentaglobin (n = 10)

80 ± 5

78 ± 10

72 ± 9*

  

 Placebo (n = 9)

79 ± 9

68 ± 9**#

71 ± 7*

  

Base excess (mEq/L)

< 0.001

0.659

 Pentaglobin (n = 10)

0.4 ± 4.9

2.5 ± 3.8

5.6 ± 4.9**

  

 Placebo (n = 9)

1.2 ± 4.7

4.0 ± 4.8

5.1 ± 4.4*

  

Arterial lactate (mmol/L)

 Pentaglobin (n = 10)

1.7 [1.3–3.5]

1.5 [1.0–2.2]

1.9 [0.9–2.7]

0.682

 

 Placebo (n = 9)

1.6 [1.0–2.2]

1.4 [1.0–2.2]

1.2 [1.1–1.7]

0.755

 

Haemoglobin (g/dL)

0.460

0.356

 Pentaglobin (n = 10)

10.4 ± 1.5

10.5 ± 0.9

9.6 ± 0.9

  

 Placebo (n = 9)

9.8 ± 1.8

10.1 ± 1.3

10.0 ± 1.1

  

Platelets (*103/mmc)

0.170

0.036

 Pentaglobin (n = 10)

158 ± 98

141 ± 80

153 ± 83

  

 Placebo (n = 9)

163 ± 86

168 ± 84

136 ± 67

  

Creatinine (mg/dL)

0.284

0.522

 Pentaglobin (n = 10)

1.1 ± 0.7

1.0 ± 0.5

0.9 ± 0.4

  

 Placebo (n = 9)

1.9 ± 1.0

2.1 ± 1.6

1.8 ± 1.2

  

Bilirubin (mg/dL)

 Pentaglobin (n = 10)

0.7 [0.5–1.7]

0.8 [0.5–1.6]

0.9 [0.5–1.7]

0.356

 

 Placebo (n = 9)

1.0 [0.5–1.3]

0.9 [0.5–2.3]

0.7 [0.6–2.4]

0.515

 

Glasgow Coma Scale

 Pentaglobin (n = 10)

14 [13–15]

15 [13–15]

15 [11–15]

0.999

 

 Placebo (n = 9)

14 [10–14]

13 [9–14]

12 [10–14]

0.999

 

SOFA score

 Pentaglobin (n = 10)

9 [7–11]

9 [5–10]

7 [6–8]

0.229

 

 Placebo (n = 9)

10 [7–13]

12 [6–12]

10 [6–12]

0.544

 

Propofol (mg/kg/h, n)

 Pentaglobin (n = 10)

1.2 [0–2.4], 7

0 [0–2.6], 4

0 [0–2.6], 4

0.790

 

 Placebo (n = 9)

0.8 [0–1.6], 5

0 [0–1.1], 4

0 [0–1.6], 3

0.518

 

Remifentanil (mcg/kg/min, n)

 Pentaglobin (n = 10)

0.08 [0.04–0.09], 8

0.05 [0–0.08], 7

0.06 [0–0.10], 7

0.366

 

 Placebo (n = 9)

0.06 [0–0.10], 8

0.05 [0–0.08], 7

0.06 [0–0.10], 7

0.991

 
  1. Data are expressed as mean ± standard deviation or median [1st–3rd quartile], as appropriate
  2. MAP mean arterial pressure, HR heart rate, ScvO2 central venous oxygen saturation, SOFA Sequential Organ Failure Assessment
  3. aTwo-way analysis of variance for repeated measures (testing the effect of time) or Friedman test, as appropriate
  4. bTwo-way analysis of variance for repeated measures (testing for the interaction between time and treatment), when applicable
  5. p < 0.05, **p < 0.01 versus baseline, Two-way analysis of variance for repeated measures with Sidack’s post hoc test or Friedman test with Dunn’s post hoc test for multiple comparisons, as appropriate
  6. #p < 0.05 versus Pentaglobin group, Two-way analysis of variance for repeated measures with Sidack’s post hoc test or Mann–Whitney U test, as appropriate